New treatment lenebasum shows promise for diffuse cutaneous systemic sclerosis (dcSSc)

June 15, 2018, European League Against Rheumatism

The results of an open label extension of a phase II study presented today at the Annual European Congress of Rheumatology (EULAR 2018) demonstrate that lenabasum continues to have acceptable safety and tolerability in diffuse cutaneous systemic sclerosis (dcSSc) with no severe or serious adverse events (AE).

"There is a critical unmet need for safe and effective therapeutics for patients with dcSSc," said Professor Thomas Dörner, Chairperson of the Abstract Selection Committee, EULAR. "These results demonstrate a significant step forward in the clinical development of a potentially impactful treatment for people suffering with this devastating disease."

Systemic sclerosis is a rare but serious autoimmune disease which causes hardening and swelling of the skin, as well as joint pain, digestive problems, lung disease, and sometimes problems with the heart and kidneys. The disease occurs in around 30 people per million population per year. The diffuse cutaneous subtype (dcSSc) is even rarer, affecting just one in every four people with the disease. It is linked with early damage to internal organs, as well as painful skin thickening that quickly gets worse. Only half of people diagnosed with dcSSc will survive for 10 years or more.

Medicines for dcSSc are very limited, immunosuppressants are sometimes used although there have been relatively few trials in dcSSc patients specifically because the disease is so rare and difficult to research.

"Our results are very encouraging and reinforce the positive findings from the double-blinded placebo-controlled part of the study with regard to safety and tolerability," said Robert Spiera, M.D., Director of the Scleroderma and Vasculitis Program at Hospital for Special Surgery, Weill Cornell Medical College in New York City and principal investigator. "We look forward to continuing our investigations to assess the role of lenebasum as a new treatment option for patients with dcSSC."

Lenabasum (JBT-101) is a selective cannabinoid receptor type 2 agonist that activates resolution of in humans and reduces inflammation and fibrosis in animal models of SSc. It is a synthetic, oral, non-immunosuppressive small molecule.

The results of the initial phase II trial demonstrated that lenabasum had acceptable safety and tolerability in dcSSc and demonstrated consistent evidence of clinical benefit. In addition, changes in gene expression were shown to be consistent with biologic effects of lenabasum on pathways relevant to SSc.

Thirty-six patients, who completed the phase II trial, enrolled into the one year open-label extension (OLE) to receive lenabasum 20mg twice a day. Results suggested improvement in multiple efficacy outcomes measured both from the start of the original study and the OLE. In the 25 subjects who completed a year in the OLE, the mean improvements from the study start included an improvement in ACR CRISS score by 56%. There was also a reduction in modified Rodnan Skin Score, HAQ-DI†, Physician Global Assessment, and 5-D Itch Questionnaire by 8.6, 0.14, 0.9, and 2.3 respectively. Forced vital capacity percentage predicted was stable from study start with mean change of 0.4%.

The mean duration of treatment in the OLE was 45 weeks with 19 patients completing 60 weeks of treatment. Three subjects discontinued the trial, two due to AEs and one withdrew consent. AEs occurred in 33/36 subjects in the OLE, however only seven had AEs related to lenabasum (none of which were severe). In total, one subject had an AE considered life threatening, three severe, 21 moderate, and eight mild. One subject developed renal crisis involving two severe and one life-threatening/serious AE (deemed unrelated to lenabasum). Most common AEs across all subjects were upper respiratory tract infection (22%), urinary tract infection (14%), diarrhoea (11%), skin ulcers (11%), and mild intermediate dizziness (8%).

An international phase III clinical trial of lenabasum has been initiated with results expected in the first half of 2020.

Explore further: Clinical advances in systemic lupus erythematosus

More information: Abstract number: OP0006, DOI: 10.1136/annrheumdis-2018-eular.3512

Related Stories

Clinical advances in systemic lupus erythematosus

June 14, 2018
The results of two studies presented today at the Annual European Congress of Rheumatology (EULAR 2018) demonstrate exciting advances for individuals suffering from systemic lupus erythematosus (SLE). The first is a phase ...

Haematopoietic stem cell transplantation increases survival in systemic sclerosis patients

June 7, 2012
Initial results from an international, investigator-initiated, open label phase III trial were presented at EULAR 2012, the Annual Congress of the European League Against Rheumatism. Data indicate that haematopoietic stem ...

Drug does not reduce digital ulcers in patients with systemic sclerosis

May 10, 2016
In an article appearing in the May 10, 2016 issue of JAMA, Dinesh Khanna, M.D., of the University of Michigan Scleroderma Program, Ann Arbor, and colleagues evaluated the efficacy of the drug macitentan in reducing the number ...

New treatment shows promise for patients with rare dermatologic disease

October 31, 2017
A new treatment for a rare and often incurable condition called dermatomyositis (DM) reduced the severity of the disease in patients whose DM was resistant to other therapies. As part of a randomized, double-blind study conducted ...

Shock-wave therapy successfully treats finger ulcers in scleroderma patients

November 5, 2017
Extracorporeal shock-wave therapy at low energy levels showed promise as a new treatment for digital ulcers in patients with systemic sclerosis, or scleroderma, according to new research findings presented this week at the ...

Recommended for you

Dietary carbohydrates could lead to osteoarthritis, new study finds

August 9, 2018
Do your knees ache? According to new findings from the Oklahoma Medical Research Foundation, your diet could be a culprit.

Joint study raises questions about treatments for arthritis

August 3, 2018
A study examining how molecules are transported into knee-joint tissue could have major implications for understanding and treating arthritis.

Researchers identify new arthritis severity gene

July 26, 2018
A new gene associated with disease severity in models of rheumatoid arthritis has been identified by researchers at the Icahn School of Medicine at Mount Sinai. The discovery could provide a new pathway for treatment and ...

How the brain plays a role in rheumatoid arthritis inflammation

June 18, 2018
In patients with chronic inflammatory conditions, such as rheumatoid arthritis, there has been limited understanding of how this inflammation affects the brain.

New 3-D imaging analysis technique could lead to improved arthritis treatment

June 18, 2018
An algorithm to monitor the joints of patients with arthritis, which could change the way that the severity of the condition is assessed, has been developed by a team of engineers, physicians and radiologists led by the University ...

Joint resolution: A link between Huntington's disease and rheumatoid arthritis

May 15, 2018
Using new analytic tools, researchers at University of California San Diego School of Medicine and the Icahn School of Medicine at Mount Sinai have decoded the epigenetic landscape for rheumatoid arthritis (RA), a common ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.